Drugs that contain Lorcaserin Hydrochloride
1. Belviq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8367657 | EISAI INC | Processes for preparing 3-benzazepines |
Apr, 2023
(1 year, 24 days ago) | |
| US8546379 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 24 days ago) | |
| US8697686 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride |
Dec, 2025
(1 year, 7 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8273734 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 24 days ago) | |
| US6953787 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 24 days ago) | |
| US8575149 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 24 days ago) | |
| US8207158 | EISAI INC | 5HT2c receptor modulators |
Apr, 2023
(1 year, 24 days ago) | |
| US7977329 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 24 days ago) | |
| US7514422 | EISAI INC | 5HT2c receptor modulators |
Apr, 2023
(1 year, 24 days ago) | |
| US7169401 | EISAI INC | Topical skin care composition containing refined peanut oil |
Jul, 2023
(9 months ago) | |
| US8946207 | EISAI INC | Processes for preparing 3-benzazepines |
Jun, 2024
(a month from now) | |
| US8980881 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
Dec, 2025
(1 year, 7 months from now) | |
| US8168624 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
Apr, 2029
(4 years from now) | |
| US9770455 | EISAI INC | Administration of an anti-obesity compound to individuals with renal impairment |
Aug, 2031
(7 years from now) | |
| US9169213 | EISAI INC | Method of weight management |
Dec, 2032
(8 years from now) | |
| US8999970 | EISAI INC | Administration of an anti-obesity compound to individuals with renal impairment |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
NCE-1 date: 27 June, 2016
Market Authorisation Date: 27 June, 2012
Treatment: Method for chronic weight management by treating obesity; Method for chronic weight management by controlling weight gain; Method for chronic weight management; Method for chronic weight management by...
Dosage: TABLET;ORAL
BELVIQ family patents
2. Belviq Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8367657 | EISAI INC | Processes for preparing 3-benzazepines |
Apr, 2023
(1 year, 24 days ago) | |
| US6953787 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 24 days ago) | |
| US8546379 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 24 days ago) | |
| US7977329 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 24 days ago) | |
| US8697686 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride |
Dec, 2025
(1 year, 7 months from now) | |
| US8168624 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
Apr, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8273734 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 24 days ago) | |
| US8207158 | EISAI INC | 5HT2c receptor modulators |
Apr, 2023
(1 year, 24 days ago) | |
| US8575149 | EISAI INC | 5HT2C receptor modulators |
Apr, 2023
(1 year, 24 days ago) | |
| US7514422 | EISAI INC | 5HT2c receptor modulators |
Apr, 2023
(1 year, 24 days ago) | |
| US8946207 | EISAI INC | Processes for preparing 3-benzazepines |
Jun, 2024
(a month from now) | |
| US8980881 | EISAI INC | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride |
Dec, 2025
(1 year, 7 months from now) | |
| US9770455 | EISAI INC | Administration of an anti-obesity compound to individuals with renal impairment |
Aug, 2031
(7 years from now) | |
| US10226471 | EISAI INC | Modified-release dosage forms of 5-HT2C agonists useful for weight management |
Aug, 2031
(7 years from now) | |
| US10463676 | EISAI INC | Modified-release dosage forms of 5-HT2C agonists useful for weight management |
Aug, 2031
(7 years from now) | |
| US9169213 | EISAI INC | Method of weight management |
Dec, 2032
(8 years from now) | |
| US8999970 | EISAI INC | Administration of an anti-obesity compound to individuals with renal impairment |
Feb, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 27, 2017 |
NCE-1 date: 27 June, 2016
Market Authorisation Date: 15 July, 2016
Treatment: Method for chronic weight management by controlling weight gain; Method for chronic weight management; Method for chronic weight management by treating obesity; Method for chronic weight management in...
Dosage: TABLET, EXTENDED RELEASE;ORAL
BELVIQ XR family patents